A newly developed TGF-β-responsive CAR T cell for enhanced proliferation and cytokine secretion
Our findings demonstrate that the TGF-βRII CAR T cells not only resist TGF-β-mediated suppression but also promote activation, proliferation, and cytokine release in the presence of TGF-β. This underscores their therapeutic potential as an innovative approach to overcome TGF-β-driven immunosuppression and improve the CAR T cell therapy efficacy in solid tumors.
Authors
- Zahra Sharifzadeh (ORCID: https://orcid.org/0000-0002-4419-0315)
- Shafieeh Mansoori (ORCID: https://orcid.org/0000-0003-0260-2497)
- Mohammad Ali Shokrgozar (ORCID: https://orcid.org/0000-0001-5123-4155)
- Shahriyar Abdoli (ORCID: https://orcid.org/0000-0002-4052-332X)
- Soheila Ajdary (ORCID: https://orcid.org/0000-0002-5052-2523)
- Monireh Gholizadeh (ORCID: https://orcid.org/0000-0003-3851-1503)
Institutions
- Pasteur Institute of Iran (IR)
- Tabriz University of Medical Sciences (IR)
- Golestan University (IR)
- Golestan University of Medical Sciences (IR)
Publication Details
- Journal
- Advanced Pharmaceutical Bulletin
- Published
- 2025-08-30
- DOI
- https://doi.org/10.34172/apb.025.45483
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pasteur Institute of Iran